Chadi Nabhan
Experienced in Multiple Endocrine Neoplasia Type 1

Dr. Chadi Nabhan

Hematology Oncology
974 Bristol Dr, 
Deerfield, IL 
Experienced in Multiple Endocrine Neoplasia Type 1
974 Bristol Dr, 
Deerfield, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Chadi Nabhan is a Hematologist Oncology provider in Deerfield, Illinois. Dr. Nabhan is rated as an Experienced provider by MediFind in the treatment of Multiple Endocrine Neoplasia Type 1. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Orchiectomy.

His clinical research consists of co-authoring 180 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Multiple Endocrine Neoplasia Type 1.

Specialties
Hematology Oncology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO

Locations

974 Bristol Dr, Deerfield, IL 60015

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy
Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Biological
Study Drugs: Brentuximab, Nivolumab
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Enrollment Status: Completed
Publish Date: December 01, 2021
Intervention Type: Drug, Radiation
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
Study Phase: Phase 2
A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas
A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas
Enrollment Status: Terminated
Publish Date: September 01, 2021
Intervention Type: Other, Biological, Drug
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

180 Total Publications

Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes.
Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes.
Journal: Prostate cancer and prostatic diseases
Published: August 12, 2025
Similar Doctors
Experienced in Multiple Endocrine Neoplasia Type 1
Dr. Manik A. Amin
Hematology Oncology | Oncology | Hematology
Experienced in Multiple Endocrine Neoplasia Type 1
Dr. Manik A. Amin
Hematology Oncology | Oncology | Hematology

The University Of Chicago Medical Center

5841 S Maryland Ave, 
Chicago, IL 
 (28.5 miles away)
773-702-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Manik Amin is a Hematologist Oncology specialist and an Oncologist in Chicago, Illinois. Dr. Amin is rated as a Distinguished provider by MediFind in the treatment of Multiple Endocrine Neoplasia Type 1. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Neuroendocrine Tumor, and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nabhan's expertise for a condition
ConditionClose
    View All 39 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile